WNWenjing Na

Wenjing Na

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenjing Na has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Kai Song

    College of Life Sciences, University of Chinese Academy of Sciences , Beijing 100864

    2 shared publications
  • Wei Liang

    Protein and Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China

    2 shared publications
  • Wenfeng Zeng

    National Laboratory of Biomacromolecules, Institute of Biophysics Chinese Academy of Sciences Beijing China

    2 shared publications
  • Youwang Wang

    College of Life Sciences, University of Chinese Academy of Sciences , Beijing 100864

    2 shared publications
  • Hao Wang

    School of Pharmacy Shanghai Jiao Tong University Shanghai 200240 China

    1 shared publication
  • Lingtao Jin

    Department of Molecular Medicine, University of Texas Health Science Center at San Antonio , TX 78229

    1 shared publication

Latest Publications

  • Open Access

    PKM2, the “K+ sink” in the tumor interstitial fluid

    by Wenjing Na, Wenfeng Zeng, Kai Song, Youwang Wang, Luoyang Wang, Ziran Zhao, Lingtao Jin, Ping Zhu, Wei Liang

    Wenjing Na, Wenfeng Zeng, Kai Song, Youwang Wang, Luoyang Wang, Ziran Zhao, Lingtao Jin, Ping Zhu, Wei Liang; PKM2, the “K+ sink” in the tumor interstitial


  • Open Access

    Stable IL‐2 Nano‐Assembly for Improved Anti‐Tumor Effect

    by Yudong Liu, Wenfeng Zeng, Wenjing Na, Xiuli Wei, Kai Song, Youwang Wang, Ping Zhu, Hao Wang, Wei Liang

    Interleukin 2 (IL‐2) is the first approved immune therapeutic drug to treat cancer, however various off‐target effects and intolerable dose‐related toxicities induced by high‐dose intravenous infusion regimens result in a large proportion of patients require dose reduction, preventing the widespread adoption of this treatment. To address these issues, a novel IL‐2 nano‐assembly formulation (nano‐IL‐2) is developed using distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐n‐[methoxy (polyethylene glycol)‐2000] (PEG2000‐DSPE), which is durably stable due to the high binding affinity (10–8 m level) of two components and hardly induces vascular leak or inflamed injury at the injection site. Besides, nano‐IL‐2 exerts excellent solubility, lymph‐targeting property, prolonged and stable serum IL‐2 concentration ranges, and much lower toxicities compared to commercial formulation. Monotherapy of nano‐IL‐2 shows optimal capability to control the growth of murine melanoma and colon cancer. Collectively, the present study provides a novel design strategy for lymph‐targeting IL‐2 formulation which is more suitable for subcutaneous administration with higher safety concern.